calaspargase pegol-mkn (Asparlas)

Indications

• acute lymphoblastic leukemia (ALL) in children & young adults 1 month to 21 years

Dosage

• 2,500 units/m2 IV every 21 days

Adverse effects

• elevated serum transaminases, increased serum bilirubin
• pancreatitis
• abnormal clotting studies

Mechanism of action

• maintenance of nadir serum asparaginase > 0.1 U/mL

More general terms

• antineoplastic agent (chemotherapeutic agent)